Previous 10 | Next 10 |
It can be a lot of fun buying stocks trading in the single digits. While there are a lot of bad companies down in the cheap seats, sometimes you can find some amazing bargains. Our roundtable has found three really cool biotech stocks trading under $10 a share. Here's why we like SeaS...
We highlight the promising aspects of the AGEN story. We touch upon certain catalysts in the foreseeable future. We conclude with some technical analysis of the AGEN stock. Company Snapshot Agenus, Inc. ( AGEN ), is a clinical-stage biotech firm that is attem...
The clinical-stage immuno-oncology company, Agenus ( NASDAQ: AGEN ) jumped more than 20% on Tuesday to record the best intraday rise since May 2021 on above average volumes. More than 5.4M Agenus ( AGEN ) shares have changed hands so far, compared to the 65-day ave...
Agenus was looking at a disaster last year after it pulled its BLA. However, after reporting strong early data from 1181, it looks to be on a much more solid footing. Current lows and cash balance make it very interesting. Agenus ( AGEN ) had a disruptive 2021, when ...
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will ...
Shares of Agenus (NASDAQ: AGEN) were soaring 27.7% higher as of 10:48 a.m. ET on Wednesday. The big gain came after the company announced results from a phase 1b study evaluating a combination of botensilimab and balstilimab in treating microsatellite-stable colorectal cancer (MSS C...
The shares of Agenus ( NASDAQ: AGEN ) surged ~24% in the morning hours Wednesday after the immuno-oncology company announced early-stage data for tumor candidates botensilimab and balstilimab in patients with a form of colorectal cancer. The Phase 1b study was designed t...
Gainers: Allena Pharmaceuticals ( ALNA ) +238% . Trevi Therapeutics TRVI +29% . Bellerophon Therapeutics ( BLPH ) +22% . Agenus ( AGEN ) +21% . Catalyst Biosciences CBIO +18% . Losers: Agile Therapeutics ( AGRX ) -29% . ...
Trevi Therapeutics ( TRVI ) +36% reports positive results from the Ph2b/3 PRISM trial of Haduvio in the treatment of Prurigo nodularis. Catalyst Biosciences CBIO +26% plans to distribute $65M cash to stockholders. 2U TWOU +18% as Byju's reportedly mak...
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, randomi...
News, Short Squeeze, Breakout and More Instantly...
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) ...
Friday, Agenus Inc (NASDAQ:AGEN) released updated results from its Phase 1 clinical trial of botensilimab and balstilimab (BOT/BAL) combi...
Updated Phase 1 data demonstrate a 12-month overall survival (OS) of 71% and 18-month OS of 62% Company plans to discuss encouraging Phase 2 interim results with the FDA Company plans to submit Phase 2 data to a major medical conference in the second half of 2024 Agenu...